CENP-V as a diagnostic marker for oocyte damage
CENP-V As a Potential Diagnostic Marker of Damage in Human Oocytes
This study is testing if measuring a protein called CENP-V in human eggs can help identify damage from aging and freezing, which could improve fertility treatments for older women.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | Vida Recoletas Sevilla Academic / other |
| Locations | 1 site (Seville, SEVILLA) |
| Trial ID | NCT06788379 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the levels of CENP-V protein in human oocytes to determine its potential as a diagnostic tool for assessing damage caused by aging and oocyte vitrification. The study will analyze discarded oocytes from women of advanced maternal age and control patients, both in their fresh state and after undergoing vitrification and thawing procedures. By focusing on the expression levels of CENP-V, the research seeks to understand its role in oocyte quality and the implications for fertility treatments.
Who should consider this trial
Good fit: Ideal candidates include women aged 36-45 with advanced maternal age or women aged 18-45 who have undergone oocyte vitrification.
Not a fit: Patients with conditions affecting oocyte quality, such as polycystic ovary syndrome or endometriosis, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a valuable diagnostic tool to assess oocyte quality and improve fertility outcomes for women undergoing assisted reproductive technologies.
How similar studies have performed: While the specific approach of using CENP-V as a diagnostic marker is novel, similar studies have explored protein markers in oocyte quality with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group of patients with advanced maternal age (AMA): patients aged 36-45 years with AMA etiology as the main factor of infertility undergoing controlled ovarian stimulation. * Group of patients with vitrification / thawing of their oocytes: patients between 18-45 years of age who underwent oocyte vitrification to later, in the study cycle, thaw their oocytes. In this group we contemplate two subgroups: * Patients with vitrified / thawed oocytes and AMA: between 36-45 years at the moment of oocytes vitrification. * Patients with vitrified / thawed oocytes and non-AMA: between 18-35 years at the moment of oocytes vitrification. * Group of control patients: patients and donors with normal etiology, aged 18-35 years, undergoing controlled ovarian stimulation and collection procedures. Exclusion Criteria: * Patients with pathologies affecting the oocyte quality (PCO, POI, endometriosis, oncology patients, etc.). * Patients/donors with oocyte cryopreserved by slow freezing technique.
Where this trial is running
Seville, SEVILLA
- Vida Recoletas Sevilla S.L. — Seville, Sevilla, Spain (Recruiting)
Study contacts
- Study coordinator: Esther Santamaría López
- Email: esther.santamaria@gruporecoletas.com
- Phone: +34954286274
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.